204 related articles for article (PubMed ID: 35083884)
1. Analysis of a novel immune checkpoint, Siglec-15, in pancreatic ductal adenocarcinoma.
Chen X; Mo S; Zhang Y; Ma H; Lu Z; Yu S; Chen J
J Pathol Clin Res; 2022 May; 8(3):268-278. PubMed ID: 35083884
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of Programmed Death Ligand-1 in Discriminating Patients With Lymph Node-Negative, p53-Wild-Type, or Low-BRCA1/2-Expression Pancreatic Ductal Adenocarcinoma.
Chen X; Zhang Y; Mo S; Ma H; Lu Z; Yu S; Chen J
Arch Pathol Lab Med; 2023 Apr; 147(4):465-473. PubMed ID: 35862858
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 and PD-L2 expression in pancreatic ductal adenocarcinoma and their correlation with immune infiltrates and DNA damage response molecules.
Zhang Y; Chen X; Mo S; Ma H; Lu Z; Yu S; Chen J
J Pathol Clin Res; 2022 May; 8(3):257-267. PubMed ID: 35037417
[TBL] [Abstract][Full Text] [Related]
4. Association of Sialic Acid-Binding Immunoglobulin-Like Lectin 15 With Phenotypes in Esophageal Squamous Cell Carcinoma in the Setting of Neoadjuvant Chemoradiotherapy.
Zhou S; Wang Y; Zhang R; Zeng W; Liu S; Liu S; Liu M; Yang H; Xi M
JAMA Netw Open; 2023 Jan; 6(1):e2250965. PubMed ID: 36648946
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the OX40/OX40L immunoregulatory axis combined with alternative immune checkpoint molecules in pancreatic ductal adenocarcinoma.
Chen X; Ma H; Mo S; Zhang Y; Lu Z; Yu S; Chen J
Front Immunol; 2022; 13():942154. PubMed ID: 35936015
[TBL] [Abstract][Full Text] [Related]
6. Significance of Siglec-15 expression in colorectal cancer: association with advanced disease stage and fewer tumor-infiltrating lymphocytes.
Lu Z; Cheng P; Huang F; Li J; Wang B; Zou S; Zheng Z; Peng C
J Pathol Clin Res; 2023 Mar; 9(2):121-128. PubMed ID: 36424637
[TBL] [Abstract][Full Text] [Related]
7. Expression and function of Siglec-15 in RLPS and its correlation with PD-L1: Bioinformatics Analysis and Clinicopathological Evidence.
Cui L; Tian X; Yan L; Guan X; Dong B; Zhao M; Lv A; Liu D; Wu J; Hao C
Int J Med Sci; 2022; 19(13):1977-1988. PubMed ID: 36438917
[No Abstract] [Full Text] [Related]
8. The significance of Siglec-15 expression in resectable non-small cell lung cancer.
Hao JQ; Nong JY; Zhao D; Li HY; Su D; Zhou LJ; Dong YJ; Zhang C; Che NY; Zhang SC; Lin JZ; Yang JB; Zhang HT; Wang JH
Neoplasma; 2020 Nov; 67(6):1214-1222. PubMed ID: 32749846
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 in pancreatic ductal adenocarcinoma: a retrospective analysis of 373 Chinese patients using an in vitro diagnostic assay.
Liang X; Sun J; Wu H; Luo Y; Wang L; Lu J; Zhang Z; Guo J; Liang Z; Liu T
Diagn Pathol; 2018 Jan; 13(1):5. PubMed ID: 29378617
[TBL] [Abstract][Full Text] [Related]
10. The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: A meta-analysis.
Gao HL; Liu L; Qi ZH; Xu HX; Wang WQ; Wu CT; Zhang SR; Xu JZ; Ni QX; Yu XJ
Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):95-100. PubMed ID: 29576277
[TBL] [Abstract][Full Text] [Related]
11. Dynamic change in Siglec-15 expression in peritumoral macrophages confers an immunosuppressive microenvironment and poor outcome in glioma.
Chen Q; Chen B; Wang C; Hu L; Wu Q; Zhu Y; Zhang Q
Front Immunol; 2023; 14():1159085. PubMed ID: 37234161
[TBL] [Abstract][Full Text] [Related]
12. Negative prognostic impact of PD-L1 expression in tumor cells of undifferentiated (anaplastic) carcinoma with osteoclast-like giant cells of the pancreas: study of 13 cases comparing ductal pancreatic carcinoma and review of the literature.
Hrudka J; Lawrie K; Waldauf P; Ciprová V; Moravcová J; Matěj R
Virchows Arch; 2020 Nov; 477(5):687-696. PubMed ID: 32424767
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 expression enhancement by infiltrating macrophage-derived tumor necrosis factor-α leads to poor pancreatic cancer prognosis.
Tsukamoto M; Imai K; Ishimoto T; Komohara Y; Yamashita YI; Nakagawa S; Umezaki N; Yamao T; Kitano Y; Miyata T; Arima K; Okabe H; Baba Y; Chikamoto A; Ishiko T; Hirota M; Baba H
Cancer Sci; 2019 Jan; 110(1):310-320. PubMed ID: 30426611
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC.
Wang X; Li X; Wei X; Jiang H; Lan C; Yang S; Wang H; Yang Y; Tian C; Xu Z; Zhang J; Hao J; Ren H
Signal Transduct Target Ther; 2020 Apr; 5(1):38. PubMed ID: 32300119
[TBL] [Abstract][Full Text] [Related]
15. Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival.
Danilova L; Ho WJ; Zhu Q; Vithayathil T; De Jesus-Acosta A; Azad NS; Laheru DA; Fertig EJ; Anders R; Jaffee EM; Yarchoan M
Cancer Immunol Res; 2019 Jun; 7(6):886-895. PubMed ID: 31043417
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 expression in pancreatic ductal adenocarcinoma is a poor prognostic factor in patients with high CD8
Yamaki S; Yanagimoto H; Tsuta K; Ryota H; Kon M
Int J Clin Oncol; 2017 Aug; 22(4):726-733. PubMed ID: 28314962
[TBL] [Abstract][Full Text] [Related]
17. Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma.
Tessier-Cloutier B; Kalloger SE; Al-Kandari M; Milne K; Gao D; Nelson BH; Renouf DJ; Sheffield BS; Schaeffer DF
BMC Cancer; 2017 Sep; 17(1):618. PubMed ID: 28870260
[TBL] [Abstract][Full Text] [Related]
18. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of PD-L1 and Siglec-15 expression in patients with nasopharyngeal carcinoma.
Zhao J; Yang H; Hu H; Liu C; Wei M; Zhao Y; Chen Y; Cui Y; Chen P; Xiong K; Lu Y; Yang H; Yang L
Sci Rep; 2022 Jun; 12(1):10401. PubMed ID: 35729260
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma.
Diana A; Wang LM; D'Costa Z; Allen P; Azad A; Silva MA; Soonawalla Z; Liu S; McKenna WG; Muschel RJ; Fokas E
Oncotarget; 2016 Jul; 7(27):40992-41004. PubMed ID: 27329602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
